We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
Annaly Capital Management
NLY
$17.4B
| $101K | ﹤0.01% |
2,700
+750
| +38% | +$27.3K |
|
1202
Protolabs
PRLB
$1.78B
| $101K | ﹤0.01% |
999
-1,254
| -56% | -$124K |
|
1203
U-Haul Holding Co
UHAL
$14.3B
| $101K | ﹤0.01% |
2,700
+100
| +4% | +$3.8K |
|
|
PGTI
1204
DELISTED
PGT, Inc.
PGTI
| $101K | ﹤0.01% |
6,835
+196
| +3% | +$3.12K |
|
|
ANZ
1205
DELISTED
AUSTRALIA & NW ZEAL ADS(RP5 SH
ANZ
| $101K | ﹤0.01% |
5,846
+777
| +15% | +$13.4K |
|
|
HES
1206
DELISTED
Hess
HES
| $100K | ﹤0.01% |
1,505
-35
| -2% | -$2.29K |
|
1207
VanEck Oil Services ETF
OIH
$1.99B
| $99K | ﹤0.01% |
375
-459
| -55% | -$110K |
|
1208
Criteo
CRTO
$1.06B
| $98K | ﹤0.01% |
5,668
+171
| +3% | +$3.04K |
|
1209
T-Mobile US
TMUS
$196B
| $98K | ﹤0.01% |
1,261
+304
| +32% | +$23.9K |
|
|
SRNE
1210
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $98K | ﹤0.01% |
29,135
| – | – |
|
|
NJ
1211
DELISTED
NIDEC CP (NIHON KABUSHIKI KAISHA)1 ADS REPTG .25 SH COM STK
NJ
| $98K | ﹤0.01% |
2,844
-40
| -1% | -$1.38K |
|
|
MACE
1212
DELISTED
MACE SECURITY INTL INC NEW
MACE
| $98K | ﹤0.01% |
395,610
| – | – |
|
|
AERI
1213
DELISTED
Aerie Pharmaceuticals
AERI
| $97K | ﹤0.01% |
4,024
+528
| +15% | +$10.9K |
|
1214
APA Corp
APA
$12.3B
| $96K | ﹤0.01% |
3,776
-4,740
| -56% | -$107K |
|
1215
Northwest Natural Holdings
NWN
$2.18B
| $96K | ﹤0.01% |
1,311
+95
| +8% | +$6.56K |
|
1216
Unum
UNM
$14B
| $96K | ﹤0.01% |
3,306
-71,597
| -96% | -$2.08M |
|
|
IMMU
1217
DELISTED
Immunomedics Inc
IMMU
| $95K | ﹤0.01% |
4,533
+472
| +12% | +$8.33K |
|
1218
Baidu
BIDU
$35.7B
| $94K | ﹤0.01% |
751
+160
| +27% | +$18.2K |
|
|
TWTR
1219
DELISTED
Twitter, Inc.
TWTR
| $94K | ﹤0.01% |
2,957
-1,123
| -28% | -$36.9K |
|
|
ECHO
1220
DELISTED
Echo Global Logistics, Inc.
ECHO
| $94K | ﹤0.01% |
4,553
| – | – |
|
1221
Acuity Brands
AYI
$10.3B
| $93K | ﹤0.01% |
676
+312
| +86% | +$40.1K |
|
1222
Brookfield Renewable
BEP
$9.7B
| $93K | ﹤0.01% |
+3,753
| New | +$88.6K |
|
1223
BlackLine
BL
$1.87B
| $93K | ﹤0.01% |
1,810
+850
| +89% | +$42.4K |
|
|
CGC
1224
Canopy Growth
CGC
$377M
| $93K | ﹤0.01% |
446
-140
| -24% | -$27.8K |
|
1225
Chefs' Warehouse
CHEF
$4.09B
| $93K | ﹤0.01% |
2,448
+1,248
| +104% | +$45.4K |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.